Drug Drug Interaction
What is the DDI Module?
The DDI Module in GastroPlus® allows you to predict mechanistic and static drug-drug interactions (DDIs) among drugs and metabolites. The ability to accurately estimate potential DDIs in silico has several benefits for pharmaceutical companies:
- Explore possible effects on the pharmacology and toxicology of drugs
- Identify species-specific changes to estimate how a drug behaves in animals vs. humans
- Investigate the safety profile of drugs that are co-administered prior to filing regulatory submissions with the FDA, EMA, and other agencies
Resources
-
Prediction of Omeprazole’s Disposition and Drug-Drug Interactions Using A Physiologically-Based Pharmacokinetic Model
DownloadDownload the poster presented at the ADMET Europe 2010 conference on the development of PBPK models and prediction of parent & metabolite DDIs with omeprazole.
Azole Antifungals: Physiologically-Based Pharmacokinetic (PBPK) Modeling and Prediction of Drug-drug Interactions (DDIs)
DownloadDownload the poster presented at the Rosenon conference in 2009 on the development of PBPK models for common azole antifungals and DDI predictions
Mechanistic Absorption and Physiologically Based Pharmacokinetic Modeling of Itraconazole and Its Application for Drug-Drug Interaction with Midazolam in Adult Populations
Learn MoreItraconazole (ITZ) is a BCS Class II triazole antifungal (Sporanox; Janssen Pharmaceutica, Titusville, NJ). It is a substrate and potent inhibitor of CYP3A4. The primary metabolite hydroxy-itraconazole...
